Human enteroviruses distributed worldwide are causative agents of a broad spectrum of diseases with extremely high morbidity, including a series of severe illnesses of the central nervous system, heart, endocrine pancreas, skeleton muscles, etc., as well as the common cold contributing to the development of chronic respiratory diseases, including the chronic obstructive pulmonary disease. The above mentioned diseases along with the significantly high morbidity and mortality in children, as well as in the high-risk populations (immunodeficiencies, neonates) definitely formulate the chemotherapy as the main tool for the control of enterovirus infections. At present, clinically effective antivirals for use in the treatment of enteroviral infection do not exist, in spite of the large amount of work carried out in this field. The main reason for this is the development of drug resistance. We studied the process of development of resistance to the strongest inhibitors of enteroviruses, WIN compounds (VP1 protein hydrophobic pocket blockers), especially in the models in vivo, Coxsackievirus B (CV-B) infections in mice. We introduced the tracing of a panel of phenotypic markers (MIC50 value, plaque shape and size, stability at 50 o C, pathogenicity in mice) for characterization of the drug-mutants (resistant and dependent) as a very important stage in the study of enterovirus inhibitors. Moreover, as a result of VP1 RNA sequence analysis performed on the model of disoxaril mutants of CVB1, we determined the molecular basis of the drug-resistance. The monotherapy courses were the only approach used till now. For the first time in the research for anti-enterovirus antivirals our team introduced the testing of combination effect of the selective inhibitors of enterovirus replication with different mode of action. This study resulted in the selection of a number of very effective in vitro double combinations with synergistic effect and a broad spectrum of sensitive enteroviruses. The most prospective attainment in our examinations in this field was the development of a novel scheme for the combined application of anti-enteroviral substances in coxsackievirus B1 neuroinfection in newborn mice. It consisted of a consecutive, alternating and non-
simultaneous administration of the substances in the combination. The triple combination -disoxaril-guanidine. HCl-oxoglaucine (DGO) showed a high effectiveness expressed in the marked reduction of the mortality rate in infected mice as compared both to the placebo group, and to the partner compounds used alone every day, and to the same combination applied simultaneously every day. The studies of the drug sensitivity of viral brain isolates from mice treated with DGO combination showed not only preserved, but even increased sensitivity to the drugs included in the combination. Obviously, the consecutive alternating administration of anti-enteroviral substances hinders the occurrence of drug-resistance in the course of the experimental enteroviral infections in mice.
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Enteroviruses in human pathology
Human enteroviruses, members of a large genus in the Picornaviridae family, are distributed worldwide and represent the most common of human viruses, possibly infecting a billion or more individuals annually and resulting in hundreds of thousands of hospitalizations per year in the developed world only (Pallansch, 2011) . Enteroviruses are very efficient infective agents although the majority of infections are asymptomatic or mild in their clinical course (Morens, 1995; Pallansch, 2006; Strauss, 2008) . The contagiousness is such that actually, if an individual in a given group developed the symptoms of an enteroviral infection, it would be certain that all members of the group were infected (Pallansch, 2011) . Alongside the asymptomatic or mild clinical course of the majority of infections, a wide variety of diverse syndromes and diseases are associated with non-polio enterovirus infections. The most common clinical manifestation is the upper respiratory tract discomfort (Chuang, 2010) , fever, and, occasionally, mild gastrointestinal symptoms (Morens, 1995) . But non-polio enteroviruses may cause a broad spectrum of diseases due to their ability to affect various organs and systems including the central nervous system, the respiratory system, the skin, the heart, the pancreas, the eyes. The most common tissue specific localization of the enteroviral infection is the central nervous system, resulting in aseptic meningitis, or much more rarely, in encephalitis. Some enteroviruses may manifest tropism to other definite tissues like the cardiotropic coxsackieviruses or those viruses affecting the pancreatic beta cells, but the tropism is neither unique, nor specific (Archard, 1987; Tauriainen, 2011) . Disseminated infection can lead to exanthema, non-specific myalgias or severe multiorgan disease in neonates (Morens, 1995) . Individual serotypes can be associated with different clinical manifestations and vice versa, a particular clinical manifestation can be caused by several different serotypes (Strauss, 2008) . Severe and life-threatening conditions, such as meningitis, encephalitis, neonatal sepsis, myocarditis, pancreatitis, as well as further complications and some chronic diseases later in life, i.g. insulin dependent type 1 diabetes mellitus (Hyoty, 2002; Galabov and Angelova, 2006) and dilated cardiomyopathy (Schultheiss, 2006) can be attributed to an enterovirus infection, especially early in life. Symptomatic infections include also the summer cold, herpangina, hand-foot-and-mouth disease, pleurodynia (Bornholm disease), rashes, hemorrhagic conjunctivitis, uveitis, chronic fatigue syndrome. Human rhino viruses, which comprise another numerous group within the enterovirus genus, cause the common cold in individuals of all ages contributing to the possible development or exacerbation of chronic respiratory diseases later in life (Tan, 2005; Mallia, 2007) . All enteroviruses due to their high stability in the environment can also be the causative agents of nosocomial outbreaks, particularly severe in neonatal units and nurseries (Aitken, 2001) .
Chemotherapy in the control of enterovirus infections
As the number of human enteroviruses is quite big and their mutation rate is rather high, it is considered that efforts for the development of a successful vaccine would not lead to an efficient control. This definitely formulates chemotherapy as the main tool to overcome the infection. What is more, the new strategy for poliomyelitis eradication claims for the development of safe and efficient anti-polio drugs.
More than a thousand substances have been screened and characterized as selective inhibitors of enterovirus replication after testing in cell culture experiments (  WIN 54954 -well tolerated in Phase I; applied orally it effectively reduced the severity of coxsackievirus A21-induced natural mild respiratory infections; lack of effect against experimentally induced infections caused by rhinovirus 23 and 29 (Tutner et al., 1993) ; rapidly metabolized; induced reversible hepatitis (Diana et al., 1995) ; adverse effects (flushing, rush) precluded further development.
 Pleconaril (WIN63843) -rate of metabolism strongly reduced (Diana et al., 1995) ; displayed some efficacy in 2 of 3 neonates with enteroviral hepatitis (Aradottir et al., 2001) ; marked efficacy against chronic meningoencephalitis (78% improvement adverse effects been minimal) (Rotbart and Webster, 2001) ; no efficacy in another double-blind trial in children with enteroviral meningitis, twice as many adverse effects have been registered (Abzug et al., 2003) ; in phase III double-blind placebo-controlled trial some efficacy was shown in coxsackievirus rhinovirus A21-induced respiratory infections (common cold) when the treatment start within 24 hours of symptom onset (Hayden et al., 2003) ; drug-increased levels of the CYP3A4 liver microsomal enzyme stopped further trials, as decided by FDA in 2002 (Senior, 2002) .
Schering-Plough carried in 2006-07 a placebo-controlled study of the effects of pleconaril nasal spray on common cold symptoms and asthma exacerbations following rhinovirus exposure (Clinical Trials.gov.U.S. NIH, 2007) , the results of which have not yet been announced. In meanwhile, pleconaril manifested properties of a virucidal for hand treatments for prevention of rhinovirus infection (Turner and Hendley, 2005) . 
The drug-resistance problem
At present it is explicitly demonstrated that the main reason for the lack of antivirals in clinical use for enterovirus infections is the development of drug-resistance. The first description of drug-resistance in enteroviruses is done by Melnick et al. as early as in 1961. Later drug-resistant enterovirus mutants have been isolated to approximately all specific enteroviral replication inhibitors (Loddo, 1980) . Since this time Herrmann and Herrmann (1977) have postulated that the drug-resistance development is an indicator of the specific antiviral activity.
The resistance to one of the best inhibitors of enteroviruses, the WIN compound disoxaril, was studied by our research team either in vitro, or in vivo (in mice) in an experimental coxsackie B (CV-B) virus infection. The tracing of a panel of phenotypic markers for the characterization of disoxaril drug-resistant and drug-dependent mutants is introduced as a very important stage in the study of enterovirus inhibitors (Table 3) (Nikolova and Galabov, 2003) . Moreover, our findings represent the first development of drug-resistance to a WIN compound on a model in vivo. Our experiments reveal that the failure of the disoxaril treatment course is due to the accumulation of drug-resistant progeny in the target organ, i.e. the mouse brain. The in vivo and in vitro generated disoxaril-resistant CV-B1 mutants demonstrate almost identical phenotype characteristics. The determination of specific phenotypic markers in the drug resistant progeny is of a special importance and is recommended as an obligatory requirement in the experimental chemotherapy of viral infections in general.
The molecular genetic analysis of the primary structure of CV-B1 VP1 mutants of the internal segment 196-258 showed that it is highly changed in the disoxaril-resistant and in disoxaril-dependent mutants in comparison to referent wild disoxaril-sensitive (REF/SOF) structures (Nikolova et al., 2011) . The sequence changes obtained give a satisfactory explanation for the mutant resistance. However, the CV-B1 disoxaril-dependent mutation and mutant behavior cannot be explained based on 1D-sequencing only. The experimental evidence that CV-B1/disoxaril-dependent mutant needs disoxaril to provoke virus coating requires further studies to determine the 3D structure of the target VP1 protein. Such approach could contribute to the characterization of the CVB1/disoxaril-resistant mutant and would clarify the nature of disoxaril-resistance and dependence. 
Combinations of antivirals against enteroviruses
Till recently mono-therapy courses have been the only approach for experimental antienterovirus chemotherapy. The resistance occurring after mono-therapy with a certain drug makes it reasonable to focus the interest on the combined administration of antiviral compounds. This approach has proven its efficacy against HIV and HCV infections and is considered as a perspective tool to be applied in a situation of pandemic flu as well. Using combined synergistic therapy, a greater effect could be achieved at lower concentrations than those required if drugs were used alone and thus the so-called "pressure of the dose" effect which favors the rapid selection of resistant mutants, would be prevented. And what is especially important and highly awaited: combining drugs would restrain the resistance phenomenon.
Testing the combined effect of selective enterovirus replication inhibitors with different mode of action is also introduced by our research team. A large-scale study of combinations has been carried out. The research on the character of the combined effects begins by careful selection of the partners. This enables the precise application of the 3D model for characterization of drug interactions, developed by Prichard and Shipman in 1990 . Thus, the synergistic effect in vitro and in vivo, of the dual combination between enviroxime and disoxaril against the replication of coxsackievirus B1 has been established Galabov, 2000, 2004) . The interactions between a series of picornavirus replication inhibitors (enviroxime, disoxaril, arildone, S-7, guanidine, PTU-23, HBB and oxoglaucine) in dual combinations has been also estimated (Nikolaeva and Galabov, 1995 , 1999a ,b, 2000 , 2004 . This large-scale study resulted in the selection of several effective double combinations with synergistic character of the combined effect in vitro.
Due to the multiple virus replication cycles taking place in the presence of the partner substances in the combinations, even the application of synergistic ones with a proven activity in vitro does not guarantee that occur-rence of single or multiple drug resistance shall be avoided.
An entirely different approach to combined application of antivirals is proposed herethe consecutive alternating administration (CAA) of triple combinations of enterovirus replication inhibitors with different mode of action. In a recent study of ours we have examined this novel approach consisting of a consecutive and alternating, not simultaneous, application of the compounds in a combination on the model of an enterovirus infection in newborn mice. The first in vivo experimental model used has been the neurotropic CV-B1 infection (VassilevaPencheva and Galabov, 2010) . Four compounds differing in their mode of antiviral action are selected for consecutive and alternating application: disoxaril (the pocket blocker, extensively studied in our laboratory, that has been established as a favorable partner in a series of synergistic combinations in vitro and in vivo), guanidine hydrochloride (targeting 2C viral protein), PTU-23 (viral RNA synthesis inhibitor, an original compound developed in our laboratory) and oxoglaucine (another original compound developed in the laboratory which attacks an early step in the virus growth cycle). The triple combination for consecutive application of disoxaril, guanidine. HCl and oxoglaucine (DGO), applied in the order of mentioning, shows a marked in vivo efficacy, expressed in a reduction of the mortality rate and lengthening of the mean survival time with 4 days as compared to that in both the placebo group, the groups in which each compound is applied daily alone, or the group when the triple combination is simultaneously applied every day (Fig. 1) . The treatment course with the DGO combination applied simultaneously results in a well expressed development of resistance to the partners. In contrast, the consecutive and alternating application of DGO results in a strong reduction of the virus content in the brain (99.9% -on the day 4, 96.8% -on day 5, 94.8% -on day 6 and 98.7% -on day 7). The drug sensitivity to the partners is not only preserved but even increased through the treatment course (Table 4) . Thus, it is demonstrated for the first time that preservation of the antiviral activity is possible if a triple combination of anti-enteroviral inhibitors is applied in a consecutive and alternating manner (not simultaneously) (Vassileva-Pencheva and Galabov, 2010) . **P < 0.005 compared to placebo. Statistical analysis was determined 7 by log rank test. Our model of a triple combination and the entirely different approach for a conescutive application of the partners undoubtedly prevents the occurrence of resistance, which is in a full contrast to the multiple drug-resistance established in the regimens when compounds are administered simultaneously every day. The way of ordering the partners plays a key role for the effectiveness of the combination. The proposed novel regimen for a combined chemotherapy must start with an inhibitor of an early step of the viral cycle, e.g. disoxaril, and must be followed by a RNA replication inhibitor, such as guanidine.HCl, and then one that targets an early step again, like oxoglaucine. This treatment course confirmed its efficacy in three models of CVB infections in vivo. (Vassileva-Pencheva and Galabov, 2010; VassilevaPencheva and Galabov, unpublished data) . The CAA treatment course confirmed its efficacy in CV-B1 neuroinfection in mice through replacing disoxaril with another WIN compoundpleconaril (Stoyanova et al., unpublished data) .
We assume that other successful models of consecutively administered triple combinations could be researched and developed and that would be the basis of a new therapeutic strategy. Хуманите ентеровируси дистрибуирани низ целиот свет се предизвикувачки агенси на широк спектар на болести со екстремно висок морбидитет, вклучително и серија тешки бо-лести на централниот нервен систем, срцето, ен-докриниот панкреас, мускулите на скелетот, итн., како и обичната настинка што придонесува за развој на хроничните респираторни болести, вклучувајќи го хроничното опструктивно бело-дробно заболување. Горенаведените болести, заедно со значително високиот морбидитет и морталитет кај децата, како и кај популациите со висок ризик (имунодефициенција, новороде-ни), дефинитивно, ја формулираат хемотерапи-јата како главна алатка за контрола на ентерови-русните инфекции. Во моментов не постојат клинички ефективни антивирусни лекови за употреба во лекувањето на ентеровирусната ин-фекција, и покрај големиот труд вложен на ова поле. Главна причина за ова е развојот на от-порноста на лекови. Ние го студиравме проце-сот на развој на отпорноста на најсилните инхи-битори на ентеровируси, WIN-соединенија (VP1 protein hydrophobic pocket blockers), особено кај моделите ин виво, Coxsackievius B (CV-B) ин-фекциите кај глувците. Воведовме следење на панел на фенотипските маркери (MIC50 вред-ност, обликот и големина на плочката, стабил-ност на 50 o C, патогеноста кај глувци) за карак-теризација на лековите-мутанти (отпорни и за-висни), како многу важна фаза во студијата на ентеровирусните инхибитори. Згора на тоа, како резултат на VP1 РНК секвентната анализа на-правена врз модел на disoxaril мутанти на CVB1, ја одредивме молекуларната основа на отпор-носта на лекови.
Монотерапевтските начини беа единстве-ниот пристап што се користеше досега. Прв пат во истражувањето на антиентеровирусните ан-тивируси нашиот тим воведе тестирање на ком-биниран ефект на селективни инхибитори на ентеровирусна репликација со различен начин на дејство. Ова истражување резултираше со избор на голем број многу ефикасни ин витро двојни комбинации со синергистичко дејство и широк спектар на чувствителни ентеровируси. Најпроспективното постигнување во нашите ис-тражувања од оваа област беше развојот на нова шема за комбинираната примена на антиенте-ровирусните супстанции во coxsackievirus B1 невроинфекцијата кај новородени глувци. Тоа се состоеше од последователно, наизменично и несимултано давање на супстанциите во комби-нација. Тројната комбинација -disoxaril-guanidine. HCl-oxoglaucine (DGO) покажа висока ефи-касност изразена во означено намалување на стапката на смртност кај заразените глувци во споредба со плацебо-групата, и со партнерските соединенија што се користат сами секој ден, а на истата комбинација што се применува исто-времено секој ден. Студиите за чувствителноста на изолатите на вирус од мозок од глувци, тре-тирани со DGO-комбинација, покажаа не само зачувана, но дури и зголемена чувствителност на лековите вклучени во комбинацијата. Очи-гледно, последователното наизменично давање антиентеровирусни супстанции го спречува јаву-вањето на отпорност на лекови во текот на експе-рименталната ентеровирусна инфекција кај глув-ците.
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